Home Healthcare Pharmaceuticals Aminoglycosides Market

Aminoglycosides Market Size, Share & Trends Analysis Report By Product (Amikacin, Paromomycin, Gentamicin, Neomycin, Tobramycin, Streptomycin, Kanamycin, Others), By Route of Administration (Oral, Topical, Injectable, Others), By Application (Skin Infection, Respiratory diseases, UTI & Pelvic Diseases, Veterinary, Other diseases) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 19, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Aminoglycosides Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Amikacin
    2. Paromomycin
    3. Gentamicin
    4. Neomycin
    5. Tobramycin
    6. Streptomycin
    7. Kanamycin
    8. Others
  2. Aminoglycosides Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Topical
    3. Injectable
    4. Others
  3. Aminoglycosides Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Skin Infection
    2. Respiratory diseases
    3. UTI & Pelvic Diseases
    4. Veterinary
    5. Other diseases
  4. Regional Aminoglycosides Market
    1. North America
      1. North America Aminoglycosides Market By Product 2022-2034 (USD MILLION/ Units)
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
      2. North America Aminoglycosides Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Topical
        3. Injectable
        4. Others
      3. North America Aminoglycosides Market By Application 2022-2034 (USD MILLION/ Units)
        1. Skin Infection
        2. Respiratory diseases
        3. UTI & Pelvic Diseases
        4. Veterinary
        5. Other diseases
      4. U.S.
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      5. Canada
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
    2. Europe
      1. Europe Aminoglycosides Market By Product 2022-2034 (USD MILLION/ Units)
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
      2. Europe Aminoglycosides Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Topical
        3. Injectable
        4. Others
      3. Europe Aminoglycosides Market By Application 2022-2034 (USD MILLION/ Units)
        1. Skin Infection
        2. Respiratory diseases
        3. UTI & Pelvic Diseases
        4. Veterinary
        5. Other diseases
      4. U.K.
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      5. Germany
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      6. France
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      7. Spain
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      8. Italy
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      9. Russia
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      10. Nordic
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      11. Benelux
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      12. Rest of Europe
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
    3. APAC
      1. APAC Aminoglycosides Market By Product 2022-2034 (USD MILLION/ Units)
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
      2. APAC Aminoglycosides Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Topical
        3. Injectable
        4. Others
      3. APAC Aminoglycosides Market By Application 2022-2034 (USD MILLION/ Units)
        1. Skin Infection
        2. Respiratory diseases
        3. UTI & Pelvic Diseases
        4. Veterinary
        5. Other diseases
      4. China
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      5. Korea
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      6. Japan
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      7. India
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      8. Australia
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      9. Taiwan
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      10. South East Asia
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      11. Rest of Asia-Pacific
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
    4. Middle East and Africa
      1. Middle East and Africa Aminoglycosides Market By Product 2022-2034 (USD MILLION/ Units)
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
      2. Middle East and Africa Aminoglycosides Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Topical
        3. Injectable
        4. Others
      3. Middle East and Africa Aminoglycosides Market By Application 2022-2034 (USD MILLION/ Units)
        1. Skin Infection
        2. Respiratory diseases
        3. UTI & Pelvic Diseases
        4. Veterinary
        5. Other diseases
      4. UAE
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      5. Turkey
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      6. Saudi Arabia
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      7. South Africa
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      8. Egypt
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      9. Nigeria
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      10. Rest of MEA
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
    5. LATAM
      1. LATAM Aminoglycosides Market By Product 2022-2034 (USD MILLION/ Units)
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
      2. LATAM Aminoglycosides Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Topical
        3. Injectable
        4. Others
      3. LATAM Aminoglycosides Market By Application 2022-2034 (USD MILLION/ Units)
        1. Skin Infection
        2. Respiratory diseases
        3. UTI & Pelvic Diseases
        4. Veterinary
        5. Other diseases
      4. Brazil
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      5. Mexico
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      6. Argentina
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      7. Chile
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      8. Colombia
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
      9. Rest of LATAM
        1. Amikacin
        2. Paromomycin
        3. Gentamicin
        4. Neomycin
        5. Tobramycin
        6. Streptomycin
        7. Kanamycin
        8. Others
        9. Oral
        10. Topical
        11. Injectable
        12. Others
        13. Skin Infection
        14. Respiratory diseases
        15. UTI & Pelvic Diseases
        16. Veterinary
        17. Other diseases
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.